N@N

Kyle Mikson Maintained (TXG) at Strong Buy with Decreased Target to $32 on, Jul 23rd, 2024

Kyle Mikson of Canaccord Genuity, Maintained "10x Genomics, Inc." (TXG) at Strong Buy with Decreased Target from $50 to $32 on, Jul 23rd, 2024.

Kyle has made no other calls on TXG in the last 4 months.

There are 11 other peers that have a rating on TXG. Out of the 11 peers that are also analyzing TXG, 7 agree with Kyle's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Rachel Vatnsdal of "JP Morgan" Downgraded from Buy to Hold and Decreased Target to $20 on, Thursday, July 18th, 2024
• Derik De Bruin of "B of A Securities" Maintained at Hold with Decreased Target to $25 on, Thursday, July 18th, 2024
• Justin Bowers of "Deutsche Bank" Downgraded from Strong Buy to Hold and Decreased Target to $25 on, Wednesday, July 10th, 2024
• Doug Schenkel of "Wolfe Research" Downgraded from Buy to Hold on, Thursday, June 27th, 2024
• Subbu Nambi of "Guggenheim" Downgraded from Strong Buy to Hold on, Wednesday, June 26th, 2024
• Dan Brennan of "TD Cowen" Downgraded from Strong Buy to Hold and Decreased Target to $32 on, Wednesday, May 1st, 2024
• Dan Leonard of "UBS" Maintained at Hold with Decreased Target to $30 on, Wednesday, May 1st, 2024

These are the ratings of the 4 analyists that currently disagree with Kyle

---

• Tycho Peterson of "Jefferies" Upgraded from Hold to Strong Buy and Held Target at $24 on, Monday, July 22nd, 2024
• Daniel Arias of "Stifel" Maintained at Strong Buy with Decreased Target to $25 on, Tuesday, July 16th, 2024
• Matthew Sykes of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $16 on, Tuesday, July 9th, 2024
• Luke Sergott of "Barclays" Maintained at Buy with Decreased Target to $24 on, Friday, June 28th, 2024

Contributing Sources

---